Passage Bio, Inc. (PASG)

Passage Bio's stock has experienced volatility over the past six months. As of early February 2026, the share price was around $10.57, a decrease of -6.79% from the prior week, and shares have traded between $5.12 and $20.20 over the past year. Key events impacting the stock include a 1-for-20 reverse stock split on July 14, 2025, Q2 2025 financial results reporting cash, cash equivalents, and marketable securities of $57.6 million as of June 30, 2025, with a projected cash runway into Q1 2027, and Q1 2025 financial results reporting cash, cash equivalents and marketable securities of $63.4 million as of March 31, 2025, also with a cash runway into Q1 2027. The company completed dosing of FTD-GRN Cohort 2 in the upliFT-D study and reported updated interim data and opened enrollment for FTD-C9orf72 patients in the upliFT-D study. The stock has underperformed both the US Biotechs industry and the broader US Market over the past year.

Demand for Passage Bio's products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the prevalence of the specific rare diseases it targets and the progress and success of its clinical trials and regulatory approvals.

Passage Bio, Inc. is a clinical-stage genetic medicines company in the healthcare sector, specifically the biotechnology industry, focusing on gene therapies for rare, monogenic central nervous system disorders. The company uses an AAV gene therapy platform developed with the University of Pennsylvania to deliver functional genes to affected areas. Its major product candidates include PBGM01 for GM1 gangliosidosis, PBFT02 for frontotemporal dementia, PBKR03 for Krabbe disease, and other programs targeting metachromatic leukodystrophy, amyotrophic lateral sclerosis and Huntington's disease.

Passage Bio, Inc. is headquartered in Philadelphia, Pennsylvania, United States. Clinical trials for PBFT02 have active sites in the United States and Brazil, with efforts to activate additional sites globally. The company has global commercial rights to all its product candidates.

Passage Bio aims to provide life-transforming gene therapies for patients suffering from rare, monogenic CNS diseases. The company emphasizes its strategic collaboration with the University of Pennsylvania's Gene Therapy Program. The company has highlighted its commitment to advancing its pipeline, particularly PBFT02, and meticulously managing expenses to extend its cash runway. The positive interim data from the upliFT-D clinical trial for PBFT02 also contributes positively to its scientific and clinical reputation.

Passage Bio, Inc. has a significant number of institutional owners, with 31 institutional owners and shareholders holding a total of 1,572,532 shares. Major institutional owners include Lynx1 Capital Management LP, Vestal Point Capital, LP, Vanguard Group Inc, Erste Asset Management GmbH, Renaissance Technologies Llc, Tang Capital Management Llc, Orbimed Advisors Llc, BlackRock, Inc., Geode Capital Management, Llc and Acadian Asset Management Llc. Individual insiders who own company stock include William Chou (CEO), Kathleen Borthwick (CFO), Dr. Sue Browne (CSO), Stuart M. Henderson (CBO), Eden Fucci (SVP of Technical Operations), Dr. Karl Whitney (SVP of Global Clinical Development), Mark S. Forman, Alexandros Fotopoulos, and Simona King.